Ann: PD1-Vaxx Presentation at ESMO Congress 2021 Annual Meeting, page-64

Hi O&E,

A lot of the most recent trial results (Keytruda etc) I have been reading (admittedly mostly in gastric ca) are now focusing on 1st line treatment peri-operatively, so in early diagnosis.

It’s quite a vast difference to 3rd line therapy, where cancer patients have continued to progress on existing SOC, so a far worse prognosis & potentially greater tumour burden with metastasis (where the cancer has spread to other organs in the body). This is where we are currently trialling PD1-VAXX & recently HER-VAXX in GEJ Ca.

So a BIG word of caution when doing DD & Research is to look at the cohort on the trial & exactly what stage of cancer these results are being generated from…IMU have gone for some of the most difficult to treat cancers & Stage 3-4, including HER-VAXX, so you really do need to be very discerning when reading & comparing trial results. I have mentioned this before & I have a gastric cancer study I will post shortly on the Media thread from ESMO that I think is very encouraging for our HER-VAXX results, in previously treated patients.

In the PD1-Vaxx trial, these late stage patients have not responded to prior treatment including MAbs, so the next step for these people would be Palliative treatment, if there is response & an improvement in OS, all the better.

I hope that helps